These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 27875913)

  • 1. Development and optimization of a meloxicam/β-cyclodextrin complex for orally disintegrating tablet using statistical analysis.
    Ainurofiq A; Choiri S
    Pharm Dev Technol; 2018 Jun; 23(5):464-475. PubMed ID: 27875913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement of Meloxicam Solubility Using a β-Cyclodextrin Complex Prepared via the Kneading Method and Incorporated into an Orally Disintegrating Tablet.
    Ainurofiq A; Choiri S; Azhari MA; Siagian CR; Suryadi BB; Prihapsara F; Rohmani S
    Adv Pharm Bull; 2016 Sep; 6(3):399-406. PubMed ID: 27766224
    [No Abstract]   [Full Text] [Related]  

  • 3. Formulation and evaluation of meloxicam oral disintegrating tablet with dissolution enhanced by combination of cyclodextrin and ion exchange resins.
    Samprasit W; Akkaramongkolporn P; Ngawhirunpat T; Rojanarata T; Opanasopit P
    Drug Dev Ind Pharm; 2015 Jun; 41(6):1006-16. PubMed ID: 24865111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and evaluation of orally disintegrating tablets of cilostazol-β-cyclodextrin inclusion complexes.
    Desai C; Prabhakar B
    Drug Dev Ind Pharm; 2015; 41(10):1589-607. PubMed ID: 25350555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tablet formulation containing meloxicam and beta-cyclodextrin: mechanical characterization and bioavailability evaluation.
    Ghorab MM; Abdel-Salam HM; El-Sayad MA; Mekhel MM
    AAPS PharmSciTech; 2004 Jul; 5(4):e59. PubMed ID: 15760056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preparation and evaluation of an orally fast disintegrating tablet formulation containing a hydrophobic drug.
    Comoglu T; Unal B
    Pharm Dev Technol; 2015 Jan; 20(1):60-4. PubMed ID: 24295202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An optimized commercially feasible milling technique for molecular encapsulation of meloxicam in β-cyclodextrin.
    Bandarkar FS; Vavia PR
    Drug Dev Ind Pharm; 2011 Nov; 37(11):1318-28. PubMed ID: 21506882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of inclusion complexation of meloxicam with β-cyclodextrin- and β-cyclodextrin-based nanosponges on solubility, in vitro release and stability studies.
    Shende PK; Gaud RS; Bakal R; Patil D
    Colloids Surf B Biointerfaces; 2015 Dec; 136():105-10. PubMed ID: 26364091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elastic liposomes bearing meloxicam-beta-cyclodextrin for transdermal delivery.
    Jain SK; Gupta Y; Jain A; Amin S
    Curr Drug Deliv; 2008 Jul; 5(3):207-14. PubMed ID: 18673264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tablet formulation studies on nimesulide and meloxicam-cyclodextrin binary systems.
    Nalluri BN; Chowdary KP; Murthy KV; Becket G; Crooks PA
    AAPS PharmSciTech; 2007 May; 8(2):Article 36. PubMed ID: 17622114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of orally disintegrating tablets of Perphenazine/hydroxypropyl-β-cyclodextrin inclusion complex.
    Wang L; Zeng F; Zong L
    Pharm Dev Technol; 2013; 18(5):1101-10. PubMed ID: 22759202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, Optimization and Evaluation of Orally Disintegrating Tablet of Meloxicam Using Its Menthol Based Solid Dispersions.
    Dehghani H; Taheri A; Homayouni A
    Curr Drug Deliv; 2017; 14(5):709-717. PubMed ID: 27142108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formulation of cyclodextrin inclusion complex-based orally disintegrating tablet of eslicarbazepine acetate for improved oral bioavailability.
    Desai S; Poddar A; Sawant K
    Mater Sci Eng C Mater Biol Appl; 2016 Jan; 58():826-34. PubMed ID: 26478377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and evaluation of fast-dissolving tablets of meloxicam-β-cyclodextrin complex prepared by direct compression.
    Obaidat AA; Obaidat RM
    Acta Pharm; 2011 Mar; 61(1):83-91. PubMed ID: 21406346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Application of β-cyclodextrin in the formulation of ODT tablets containing ibuprofen].
    Zimmer Ł; Kasperek R; Poleszak E
    Polim Med; 2014; 44(4):231-5. PubMed ID: 25932904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inclusion complexes of tadalafil with natural and chemically modified beta-cyclodextrins. I: preparation and in-vitro evaluation.
    Badr-Eldin SM; Elkheshen SA; Ghorab MM
    Eur J Pharm Biopharm; 2008 Nov; 70(3):819-27. PubMed ID: 18655829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Formulation and Evaluation of Baclofen-Meloxicam Orally Disintegrating Tablets (ODTs) Using Co-Processed Excipients and Improvement of ODTs Performance Using Six Sigma Method.
    Abdelmonem R; Abdellatif MM; Al-Samadi IEI; El-Nabarawi MA
    Drug Des Devel Ther; 2021; 15():4383-4402. PubMed ID: 34690500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclodextrin-based oral dissolving films formulation of taste-masked meloxicam.
    Samprasit W; Akkaramongkolporn P; Kaomongkolgit R; Opanasopit P
    Pharm Dev Technol; 2018 Jun; 23(5):530-539. PubMed ID: 29103353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Curcumin- β-Cyclodextrin Molecular Inclusion Complex: A Water-Soluble Complex in Fast-dissolving Tablets for the Treatment ofNeurodegenerative Disorders.
    Mugundhan SL; Balasubramaniyan P; Narayanasamy D; Mohan M
    Pharm Nanotechnol; 2024; 12(4):365-377. PubMed ID: 38192139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of pediatric orally disintegrating mini-tablets containing atomoxetine hydrochloride-β-cyclodextrin inclusion complex using experimental design.
    Özyılmaz ED; Comoglu T
    Drug Dev Ind Pharm; 2022 Nov; 48(11):667-681. PubMed ID: 36454038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.